Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020.
Moderna has sued Pfizer and German partner BioNTech for patent infringement regarding the development of the first COVID-19 vaccine approved in the United States, with allegations of copied technology developed by Moderna before the pandemic.
The lawsuit, filed in the US District Court in Massachusetts, will also be filed in the Regional Court of Dusseldorf, Germany. Moderna Chief Executive Stephane Bancel confirmed: “We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic.”
As two of the first groups to develop vaccines for the novel SARS-CoV-2 virus, Moderna and Pfizer/BioNTech witnessed a revenue windfall as the regulatory bodies such as the US FDA granted emergency use authorization for each vaccine. Moderna’s COVID-19 vaccine was granted emergency use authorization a week after the Pfizer/BioNTech vaccine, with the former bringing Moderna USD $10.4 billion in revenue and the latter raking in USD $22 billion for Pfizer.
A Pfizer spokesperson stated in an email statement: “We are surprised by the litigation given the COVID-19 vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer…. We will vigorously defend against all allegations of patent infringement.”
The vaccines produced by both Moderna and Pfizer/BioNTech involve mRNA technology that teaches human cells how to make a protein that will trigger an immune response. Moderna alleges that Pfizer/BioNTech leveraged mRNA technology patented by Moderna between 2010–2016, well before the outbreak of SARS-CoV-2 in 2019, for the development of their mRNA vaccine. Two types of intellectual property rights are alleged to have been infringed. One involves the mRNA structure, which Moderna claims to have begun developing in 2010. The second involves the coding of a full-length spike protein that was allegedly created while developing a vaccine for the coronavirus responsible for MERS. While Moderna has stated that the lawsuit is not meant to prevent access to COVID-19 vaccines, the pharmaceutical company, just over a decade old, claims that it does expect pharma giants such as Pfizer and BioNTech to respect their intellectual property rights.
Legal experts and analysts expect the dispute to take years. Shares for each company were down by the Friday afternoon trade.
Source: Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine | Reuters
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance